Onderzoekers van het UMCG en spin‑off CC Diagnostics, lid van de LIFE Cooperative, hebben een nieuwe test ontwikkeld die het screenen op baarmoederhalskanker mogelijk efficiënter en gebruiksvriendelijker maakt. De methode richt zich op het nauwkeuriger opsporen van afwijkende cellen en kan volgens de onderzoekers bijdragen aan een toegankelijker bevolkingsonderzoek.
Researchers at the UMCG and their spin-off CC Diagnostics, located on Campus Groningen, have developed a new test that could make cervical cancer screening more efficient and user-friendly. The method focuses on detecting abnormal cells more accurately and, according to the researchers, could contribute to more accessible population screening.
It is great to see this development taking place at the Healthy Ageing Campus, where research and entrepreneurship come together around innovations that strengthen the health of future generations.
Read the full article in Trouw here .
Source: Trouw, Renée Moezelaar (March 13, 2026).
The large-scale Lifelines population study is inviting new participants for the first time in twenty years. The study is seeking around 16,000 relatives of existing participants. This expansion has been made possible by a grant from the National Programma Groningen (NPG).
Who is developing the most impactful innovation in Life Sciences & Health in the Northern Netherlands? Five companies are in the running for the LIFE Science Innovation Award 2026: Flux Robotics, Limosa Immunodiagnostics, SPCTR, MimeCure and GlycanScan International. The nominees will present their innovations on Tuesday 22 September during the fifth edition of the LIFE Science Conference in Groningen. An independent jury will select the winner, who will receive a €10,000 cash prize.
ZonMw is expected to open the final call for proposals within the PharmaNL Shared Development Infrastructure (SDI) program line. This program line focuses on strengthening the infrastructure for the development, upscaling, and production of innovative medicines in the Netherlands.
